INTERNATIONAL: Thalidomide push from Makovsky to Europe/Australia

WARREN, NJ: Makovsky & Company will spearhead a campaign by

pharmaceutical company Celgene to expand its controversial drug

Thalidomide to European and Australian markets.



Once banned in the US, the drug was given limited FDA approval in 1998

as a treatment for leprosy. More recently, however, it has become known

as an experimental treatment for cancer.



However, the drug faces a tough market in Europe, where during the 1950s

and early 1960s, Thalidomide was prescribed to pregnant women for

morning sickness and as a sleep aid.



More than 10,000 'Thalidomide children' were born, often with extreme

deformities.



Makovksy, Thalidomide's US agency, will manage the international

expansion of the drug through its Australia and London bureaux.



The international offices will report directly to Donna Ramer, MD of

healthcare in Makovsky's New York office.



Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus

Latest Articles

Max Clifford trial jury to reconvene tomorrow after majority verdicts direction

Max Clifford trial jury to reconvene tomorrow after majority verdicts direction

The jury in the trial of celebrity publicist Max Clifford on 11 charges of indecent assault has been sent home for the day after being told by the judge earlier this afternoon that he will now accept majority verdicts.

Labour "fooling themselves" over plans to combat attacks on Miliband

Labour "fooling themselves" over plans to combat attacks on Miliband

Conservative-leaning public affairs experts have questioned the value of Labour's adoption of US-style campaigning tactics in the wake of the opposition hiring election strategist David Axelrod.

PLMR appoints Professor Tim Morris as non-executive director

The vet who helped establish the British Horseracing Authority's anti-doping and animal welfare programme has joined PLMR as a non-executive director.